

APA971Hu01 100μg Active Glypican 3 (GPC3)

Organism Species: Homo sapiens (Human)

Instruction manual

FOR RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

#### [PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Thr343~His559

Tags: N-terminal His and GST Tag

**Purity: >80%** 

**Endotoxin Level:** <1.0EU per 1μg (determined by the LAL method). **Buffer Formulation:** PBS, pH7.4, containing 0.01% SKL, 5%Trehalose .

Original Concentration: 200µg/mL

Applications: Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.0

Predicted Molecular Mass: 54.6kDa

Accurate Molecular Mass: 60kDa as determined by SDS-PAGE reducing conditions.

#### [USAGE]

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

#### [ STORAGE AND STABILITY ]

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

### [SEQUENCE]

TTIGKLCA

HSQQRQYRSA YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT LCWNGQELVE RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ QATPKDNEIS TFHNLGNVH

### [ACTIVITY]

Glypican-3 (GPC3), a 70 kDa protein, is a member of the glypican family that attaches to the cell surface by a glycosylphosphatidylinositol anchor, is specifically up-regulated in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC. GPC3 is also a negative transcriptional regulator and tumor suppressor that inhibits the growth of breast, ovary, and lung cancer cells. It is reported that GPC3 can form a complex with insulin-like growth factor 2 (IGF2), and might thereby modulate IGF2 action. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human GPC3 and recombinant rat IGF2. Briefly, GPC3 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100  $\,\mu$  I were then transferred to IGF2-coated microtiter wells and incubated for 1h at 37  $^{\circ}$ C. Wells were washed with PBST and incubated for 1h with anti-GPC3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37  $^{\circ}$ C, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes

at 37  $^{\circ}$ C . Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human GPC3 and recombinant rat IGF2 was shown in Figure 1, the EC50 for this effect is 0.08 ug/mL.




Figure 1. The binding activity of recombinant human GPC3 and recombinant rat IGF2

## [ IDENTIFICATION ]




Figure 2. Gene Sequencing (extract)

# Cloud-Clone Corp.




Figure 3. SDS-PAGE

Sample: Active recombinant GPC3, Human

### [ IMPORTANT NOTE ]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.